Shares of China Biologic Products Inc (NASDAQ:CBPO) have been assigned a consensus broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.
Brokers have set a 12 month consensus price target of $136.50 for the company and are anticipating that the company will post $0.53 EPS for the current quarter, according to Zacks. Zacks has also assigned China Biologic Products an industry rank of 73 out of 265 based on the ratings given to its competitors.
China Biologic Products (NASDAQ:CBPO) opened at 135.52 on Monday. The company has a market capitalization of $3.60 billion and a price-to-earnings ratio of 42.90. China Biologic Products has a 12 month low of $64.36 and a 12 month high of $143.21. The stock’s 50 day moving average price is $125.17 and its 200 day moving average price is $110.97.
China Biologic Products (NASDAQ:CBPO) last released its earnings results on Tuesday, November 3rd. The biopharmaceutical company reported $0.82 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.81 by $0.01. The company had revenue of $78.80 million for the quarter, compared to analysts’ expectations of $75.30 million. The company’s revenue was up 14.4% compared to the same quarter last year. Equities research analysts anticipate that China Biologic Products will post $3.35 earnings per share for the current fiscal year.
CBPO has been the topic of several analyst reports. Zacks Investment Research upgraded China Biologic Products from a “hold” rating to a “buy” rating and set a $123.00 target price on the stock in a research report on Thursday, October 29th. Credit Suisse initiated coverage on China Biologic Products in a research report on Thursday, October 8th. They issued an “outperform” rating on the stock.
In other China Biologic Products news, CEO David Gao sold 12,891 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $112.26, for a total transaction of $1,447,143.66. Following the sale, the chief executive officer now directly owns 472,991 shares of the company’s stock, valued at $53,097,969.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Zhijun Tong sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, December 7th. The stock was sold at an average price of $118.33, for a total value of $1,774,950.00. Following the sale, the director now directly owns 14,000 shares in the company, valued at $1,656,620. The disclosure for this sale can be found here.
China Biologic Products, Inc. (NASDAQ:CBPO) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries, namely, Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co., Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co., Ltd., a plasma products company. Its products include human albumin, human immunoglobulin, IVIG, thymopolypeptides injection, human hepatitis B immunoglobulin, human rabies immunoglobulin, human tetanus immunoglobulin, placenta polypeptide, Factor VIII and human prothrombin complex concentrate (PCC).
For more information about research offerings from Zacks Investment Research, visit Zacks.com